NEW YORK (GenomeWeb News) – Dalton Pharma Services will use Thermo Fisher Scientific’s enzyme-based technology to make nucleic acid biopolymers for use in drug development research projects, Toronto-base Dalton said today.
Dalton will produce poly-inosine and poly-cytosine in accordance with current good manufacturing practice regulations.
These polynucleotides are used as catalysts to stimulate immune responses when they are combined with other substances in a drug, the company said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.